Double-Pronged immune cells take aim at blood cancers

NCT ID NCT05432882

Recruiting now Disease control Sponsor: Shenzhen Geno-Immune Medical Institute Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a new type of immunotherapy called bi-specific CAR-T cells that target two proteins, CD19 and CD22, on the surface of B cell cancer cells. The treatment involves infusing these engineered immune cells into patients whose B cell malignancies have returned or not responded to standard care. The goal is to see if the approach is safe and can shrink tumors.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: bi-4SCAR CD19/22 T cells
What this could lead to: If successful, this approach could offer a new treatment option for people with B cell cancers that have not responded to other therapies.
What could go wrong: This is an early-phase trial with a small number of participants, so results may not apply broadly. CAR-T therapy can cause serious side effects like cytokine release syndrome.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for B-CELL MALIGNANCIES are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

B-cell neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

B-CELL MALIGNANCIES

Contacts and locations

Locations

Shenzhen Geno-immune Medical Institute
RECRUITING

Shenzhen, Guangdong, 518000, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.